TROY, Mich., Dec. 16, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of branded innovative solutions for the cannabis and hemp industries, has closed on its previously announced acquisition of certain assets from Double or Nothing LLC, the owner and creator of the Señorita brand of hemp-derived THC (“HD9”) drinks. “This is great news for Agrify shareholders! We believe Señorita is the best tasting drink in the fastest growing, most exciting beverage category in the country,” said Agrify Chairman and Interim CEO Ben Kovler. “Cannabis-based beverages like Señorita deliver consumers an enjoyable experience without the downsides of alcohol. This high demand is propelling Señorita founders Joel Gott and Charles Bieler with the team towards innovation and product development...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Shore Capital Stockbrokers Ltd(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Warpaint London Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Warpaint London Plc(d)        Date dealing undertaken: 13 December 2024(e)        Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? Yes – Brand Architekts Group plc2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER (a)        Purchases...

The healthcare analytical testing services market is growing due to rising clinical trials, biosimilar focus, increased outsourcing, and the impact of COVID-19. Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global healthcare analytical testing services market size will reach a value of USD 15.55 Billion by 2031, with a CAGR of 11.2% during the forecast period (2024-2031). The market’s main driving factors are the number of companies in the pharmaceutical and medical device industries that outsource analytical testing services, increased clinical trials in need of analytical testing, and the rising emphasis on biosimilars. The industry has grown as a result of the COVID-19 pandemic. Additionally, since the pandemic, the market has seen a quick development in medications and treatments for its prevention,...

The stem cell banking market is growing due to advancements in cryopreservation, cell bank prep, monoclonal antibodies, and the rising adoption of stem cell therapy. Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global stem cell banking market share will reach a value of USD 18.65 Billion by 2031, with a CAGR of 18.30% during the forecast period (2024-2031). As cryopreservation and cell bank preparation techniques are getting advanced, the stem cell banking market is expanding rapidly. Besides, the market is growing due to the increased application of stem cell treatment and the trend of monoclonal antibodies with effective biopharmaceuticals. Furthermore, with the fact that more couples are opting for children at a later stage in life, late parenting is on the rise, and it has generated interest in...

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies...

CORNELIUS, N.C. and NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) —  Alpha Modus Holdings, Inc. (“Alpha Modus” or the “Company”), a technology company with a core focus on artificial intelligence in retail, is pleased to announce that the business combination between Insight Acquisition Corp. and Alpha Modus Corp. has closed, and Alpha Modus’s common stock and warrants will begin trading on the Nasdaq Global Market under the ticker symbols “AMOD” and “AMODW”, respectively, on Monday, December 16, 2024. In connection with the closing of the business combination, the combined company consummated and issued a secured convertible promissory note to an investor, in exchange for net proceeds of approximately $2.6 million, which will be used primarily to cover transaction costs and for working capital. The structure of the financing...

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has increased its ownership interest in Brit Limited to 100% from 86.2% by acquiring the interest of OMERS, the pension plan for Ontario’s municipal employees, for cash consideration of approximately US$383 million. Fairfax is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management. For further information contact:        John Varnell, Vice President, Corporate Development at (416) 367-4941

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — Rogers Communications (TSX: RCI.A and RCI.B) (NYSE: RCI) today announced it has received clearance from the Competition Bureau to proceed with the acquisition of Bell’s 37.5% stake in Maple Leaf Sports & Entertainment. Rogers and Bell received a “no-action letter” on December 12, 2024, from the Bureau, indicating that the Commissioner of Competition does not intend to challenge Rogers acquisition of Bell’s interest in MLSE. The deal is subject to league approvals and approval from the CRTC. “This reflects an important step in securing approvals and expanding our ownership of MLSE, one of the most prestigious sports and entertainment organizations in the world,” said Tony Staffieri, President and CEO, Rogers. “As Canada’s leading communications and entertainment company,...

AleAnna Accelerates Efforts to Improve Italy’s Energy Sustainability and Security with Strategic Business CombinationCombination brings emerging leader in Italian natural gas and renewable natural gas to public markets Shares of AleAnna, Inc. to begin trading on Nasdaq on December 16 under the ticker symbol “ANNA” AleAnna stands on the cusp of a major milestone, with the first phase of natural gas production from the Longanesi Field projected to commence in Q1 2025DALLAS and VANCOUVER, British Columbia and ROME, Dec. 13, 2024 (GLOBE NEWSWIRE) — AleAnna, Inc. (together with its subsidiaries, “AleAnna” or the “Company”), an emerging leader in Italy’s energy landscape, announced the completion of the previously announced business combination (the “Business Combination”) between Swiftmerge Acquisition Corp. (NASDAQ: IVCP) (“Swiftmerge”),...

        Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated...